Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-5 of 5

Sort by

Sort Order Select

Journal Articles

The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER⁺ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

Cancer Res (2023) 83 (23): 3989–4004.

https://doi.org/10.1158/0008-5472.CAN-23-0694

Published: 01 December 2023

View article titled, The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

Includes: Supplementary data

Journal Articles

Abstract 4379: Not all selective estrogen receptor degraders are equal - Preclinical comparison of AZD9833, AZD9496 and fulvestrant

Mandy Lawson, Natalie Cureton, Michelle DuPont, Oona Delpuech, Dawn Trueman, Pei Zhang, Azadeh Cheraghchi-Bashi-Astaneh, Sladjana Gagrica, Gareth Maglennon, Daniel Sutton, Bairu Zhang, Jonathan Cairns, Jamie Scott, Teresa Klinowska, Christopher J. Morrow

Cancer Res (2020) 80 (16_Supplement): 4379.

https://doi.org/10.1158/1538-7445.AM2020-4379

Published: 15 August 2020

View article titled, Abstract 4379: Not all selective estrogen receptor degraders are equal - Preclinical comparison of AZD9833, AZD9496 and fulvestrant

Journal Articles

Abstract P6-04-15: Oral selective estrogen receptor degrader AZD9496 demonstrated preclinical model specific differences to fulvestrant in estrogen receptor degradation, agonism and anti-tumour effects

Mandy Lawson, Natalie Cureton, Oona Delpuech, Pei Zhang, Azadeh Cheraghchi-Bashi-Astaneh, Sladjana Gagrica, Dawn Trueman, Gareth Maglennon, Daniel Sutton, Bairu Zhang, Jonathan Cairns, Teresa Klinowska, Christopher J Morrow

Cancer Res (2020) 80 (4_Supplement): P6-04-15.

https://doi.org/10.1158/1538-7445.SABCS19-P6-04-15

Published: 15 February 2020

View article titled, Abstract P6-04-15: Oral selective estrogen receptor degrader AZD9496 demonstrated preclinical model specific differences to fulvestrant in estrogen receptor degradation, agonism and anti-tumour effects

Journal Articles

Abstract 4813: Comparative activity profiling of tyrosine kinase inhibitors (TKIs) against exon 20 insertions and the wild-type form of epidermal growth factor receptor (EGFR)

Richard A. Ward, Ambra Bianco, Nicola Colclough, Darren Cross, Emanuela M. Cuomo, M. Raymond V. Finlay, Martina Fitzek, Nicolas Floc’h, Sladjana Gagrica, Beverley Hammond, Matthew J. Martin, Darren McKerrecher, Daniel J. O’Neill, Jonathan P. Orme, Paul D. Smith, Anna D. Staniszewska, Jelena Urosevic, Nicky Whalley, James W. Yates

Cancer Res (2019) 79 (13_Supplement): 4813.

https://doi.org/10.1158/1538-7445.AM2019-4813

Published: 01 July 2019

View article titled, Abstract 4813: Comparative activity profiling of tyrosine kinase inhibitors (TKIs) against exon 20 insertions and the wild-type form of epidermal growth factor receptor (EGFR)

Journal Articles

Contrasting Behavior of the p18^INK4c and p16^INK4a Tumor Suppressors in Both Replicative and Oncogene-Induced Senescence

Sladjana Gagrica, Sharon Brookes, Emma Anderton, Janice Rowe, Gordon Peters

Cancer Res (2012) 72 (1): 165–175.

https://doi.org/10.1158/0008-5472.CAN-11-2552

Published: 02 January 2012

View article titled, Contrasting Behavior of the p18INK4c and p16INK4a Tumor Suppressors in Both Replicative and Oncogene-Induced Senescence

Includes: Supplementary data

NARROW

The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER⁺ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

Abstract 4379: Not all selective estrogen receptor degraders are equal - Preclinical comparison of AZD9833, AZD9496 and fulvestrant

Abstract P6-04-15: Oral selective estrogen receptor degrader AZD9496 demonstrated preclinical model specific differences to fulvestrant in estrogen receptor degradation, agonism and anti-tumour effects

Abstract 4813: Comparative activity profiling of tyrosine kinase inhibitors (TKIs) against exon 20 insertions and the wild-type form of epidermal growth factor receptor (EGFR)

Contrasting Behavior of the p18^INK4c and p16^INK4a Tumor Suppressors in Both Replicative and Oncogene-Induced Senescence

Email alerts

AACR Journals

The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

Abstract 4379: Not all selective estrogen receptor degraders are equal - Preclinical comparison of AZD9833, AZD9496 and fulvestrant

Abstract P6-04-15: Oral selective estrogen receptor degrader AZD9496 demonstrated preclinical model specific differences to fulvestrant in estrogen receptor degradation, agonism and anti-tumour effects

Abstract 4813: Comparative activity profiling of tyrosine kinase inhibitors (TKIs) against exon 20 insertions and the wild-type form of epidermal growth factor receptor (EGFR)

Contrasting Behavior of the p18INK4c and p16INK4a Tumor Suppressors in Both Replicative and Oncogene-Induced Senescence

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only

The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER⁺ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

Contrasting Behavior of the p18^INK4c and p16^INK4a Tumor Suppressors in Both Replicative and Oncogene-Induced Senescence